Full Product Name
FZD4 siRNA (Rat)
Product Synonym Names
Frizzled-4; Fz-4; rFz4; CD antigen CD344
Product Gene Name
FZD4 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9QZH0
Specificity
FZD4 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat FZD4 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of FZD4 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
FZD4 sirna
siRNA to inhibit FZD4 expression using RNA interference
Applications Tested/Suitable for FZD4 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for FZD4. It may not necessarily be applicable to this product.
NCBI Accession #
NP_072145.1
[Other Products]
NCBI GenBank Nucleotide #
NM_022623.2
[Other Products]
UniProt Primary Accession #
Q9QZH0
[Other Products]
Molecular Weight
60,355 Da
NCBI Official Full Name
frizzled-4
UniProt Protein Name
Frizzled-4
UniProt Synonym Protein Names
CD_antigen: CD344
UniProt Gene Name
Fzd4 [Similar Products]
UniProt Synonym Gene Names
Fz-4; rFz4 [Similar Products]
UniProt Entry Name
FZD4_RAT
NCBI Summary for FZD4
putative Wnt receptor; may play a role in the Wnt signaling pathway [RGD, Feb 2006]
UniProt Comments for FZD4
FZD4: Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin (CTNNB1) canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin (CTNNB1) and activation of Wnt target genes. Plays a critical role in retinal vascularization by acting as a receptor for Wnt proteins and norrin (NDP). In retina, it can be both activated by Wnt protein-binding, but also by a Wnt-independent signaling via binding of norrin (NDP), promoting in both cases beta-catenin (CTNNB1) accumulation and stimulation of LEF/TCF-mediated transcriptional programs. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Defects in FZD4 are the cause of vitreoretinopathy exudative type 1 (EVR1); also known as autosomal dominant familial exudative vitreoretinopathy (FEVR) or Criswick- Schepens syndrome. EVR1 is a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease-related abnormality is an arc of avascular retina in the extreme temporal periphery. Belongs to the G-protein coupled receptor Fz/Smo family.
Protein type: Membrane protein, multi-pass; Membrane protein, integral; GPCR, Fz/Smo family; Receptor, GPCR
Cellular Component: cell surface; plasma membrane; integral to membrane; intercellular junction
Molecular Function: G-protein coupled receptor activity; Wnt-protein binding; Wnt receptor activity; protein homodimerization activity; protein heterodimerization activity; ubiquitin protein ligase binding; cytokine binding; PDZ domain binding
Biological Process: positive regulation of JNK activity; blood vessel development; Wnt receptor signaling pathway; positive regulation of transcription, DNA-dependent; Wnt receptor signaling pathway through beta-catenin; signal transduction; progesterone secretion; locomotion during locomotory behavior; G-protein coupled receptor protein signaling pathway; Wnt receptor signaling pathway, calcium modulating pathway; sensory perception of sound; regulation of vascular endothelial growth factor receptor signaling pathway; luteinization; positive regulation of transcription factor activity; vasculogenesis
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
